Skip to main
VOR

Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma (VOR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Vor Biopharma has strategically enhanced its operations across asset management, financial stability, and leadership, positioning itself to transition into a commercial entity within the next 24-30 months. The company's product pipeline, particularly VCAR33 and Trem-cel+VCAR33 Treatment System, demonstrates promising efficacy and safety profiles that could surpass current market competitors, potentially increasing adoption rates. Positive trial data supporting significant clinical improvements in various patient populations further underscores the company’s potential for substantial growth and expansion opportunities in the therapeutic landscape.

Bears say

Vor Biopharma Inc. has experienced a significant decline in its stock price, with a recent offering price set at $10.00 per share, representing a 47% discount from the previous closing price of $18.80, indicating investor concern over valuation. The downward revision of the price target from $55 to $32 reflects apprehensions related to share dilution and the financial implications of pursuing global Phase 3 studies, despite positive data from partnerships. Compounding these challenges, there are concerns regarding the attractiveness of their treatments due to complications such as initial vaccination requirements and infection risks associated with complement inhibitors, which could hinder future market adoption.

Vor Biopharma (VOR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vor Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vor Biopharma (VOR) Forecast

Analysts have given Vor Biopharma (VOR) a Buy based on their latest research and market trends.

According to 7 analysts, Vor Biopharma (VOR) has a Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vor Biopharma (VOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.